09 August 2024

Oxford Nanopore Technologies plc

Director Declaration

Pursuant to Listing Rule 6.4.9 R(2), Oxford Nanopore Technologies plc (the "Company") confirms that Heather Preston, Non-Executive Director of the Company, was appointed to the Board of Aligos Therapeutics (Nasdaq: ALGS) as Non-Executive Director effective 7 August 2024.

[ENDS]

For further information, please contact:

Oxford Nanopore Technologies plc

Investors:         ir@nanoporetech.com

Media:              media@nanoporetech.com

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com  

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA.  The technology is used in more than 120 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture.

Oxford Nanopore devices sequence DNA and RNA directly and sequence short to ultra-long fragments of DNA, for a truly comprehensive picture of the genome. Data is streamed in real-time and can enable rapid insights.  The technology is fully scalable - from pocket-sized to ultra-high throughput devices.

For more information please visit: www.nanoporetech.com